To fill the massive revenue gap from its Keytruda patent cliff, Merck is not seeking a single replacement drug. Instead, it's adopting a "Moneyball" strategy, acquiring a portfolio of diverse, multi-billion dollar assets like Turns, Verona, and Sedara to collectively replace the lost income.
Recognizing the UK is only 3% of the global pharma market, the MHRA's strategy is to make its approval a "gateway." By forging alliances with other regulators, an MHRA approval could fast-track clearance in other countries, expanding the market opportunity for sponsors who start trials in the UK.
The acquisition of Oro highlights the success of the "NUCO" model, where Chinese biotechs like KeyMed spin out assets into new companies. These NUCOs are backed by Western VCs specifically to achieve global development and a lucrative exit, creating a repeatable pathway for Asian science to reach Western markets.
In a creative maneuver, Gilead is acquiring T-cell developer Oro while arranging for its partner, Galapagos (in which Gilead owns a 25% stake), to integrate Oro's team and co-fund development. This allows Gilead to leverage Galapagos's balance sheet to execute its own strategic acquisition.
The UK's clinical trial reforms go beyond simple regulatory tweaks by leveraging the single-payer NHS. The MHRA is creating a single national contract template to eliminate redundant, site-by-site negotiations, turning a structural feature of its healthcare system into a competitive advantage for trial efficiency.
Gilead consistently demonstrates an appetite for high-risk, novel science. From pioneering CAR-T (Kite) and new ADCs (Trodelvi) to its latest T-cell engager deal, the company's acquisition history signals a clear preference for cutting-edge platforms rather than safer, later-in-class assets.